Home / Health / New Drug Fights "Ozempic Butt" Muscle Loss
New Drug Fights "Ozempic Butt" Muscle Loss
8 Jun
Summary
- New drug apitegromab may prevent muscle loss linked to obesity jabs.
- About a third of weight loss from GLP-1 drugs can be muscle.
- Trial participants on apitegromab maintained muscle mass.
A novel drug, apitegromab, is emerging as a potential solution for individuals using obesity medications who wish to avoid significant muscle loss. Recent research, published in Nature Medicine, indicates that popular GLP-1 receptor agonist drugs, such as Wegovy and Mounjaro, can lead to substantial muscle depletion – potentially one-third of total weight loss.
A clinical trial involving 102 adults, predominantly women, explored the efficacy of apitegromab. The study found that participants who received apitegromab in conjunction with their obesity medication managed to maintain a greater proportion of muscle mass. This was evident through body scans, even as they continued to lose fat, thereby addressing concerns like the "Ozempic butt" phenomenon.
While these initial findings are encouraging, experts emphasize that further evaluation studies are necessary. These additional studies will be crucial before apitegromab can be broadly recommended for use alongside weight-loss injections to mitigate muscle loss.
